Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial

医学 传统PCI Evolocumab公司 血运重建 心脏病学 内科学 经皮冠状动脉介入治疗 支架 心肌梗塞 外科 载脂蛋白B 胆固醇 载脂蛋白A1
作者
Kazuma Oyama,Remo H M Furtado,Antônio Fagundes,Thomas A. Zelniker,Minao Tang,Julia Kuder,Sabina A. Murphy,Andrew Hamer,Huei Wang,Anthony Keech,Terje R. Pedersen,Robert P. Giugliano,Marc S. Sabatine,Brian Bergmark
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:142 (Suppl_3) 被引量:3
标识
DOI:10.1161/circ.142.suppl_3.14770
摘要

Introduction: Although PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall, their ability to specifically reduce the risk of complex coronary atherosclerosis requiring revascularization has not been explored. Methods: FOURIER was a randomized trial of the PCSK9 inhibitor evolocumab vs. placebo in 27,564 patients with ASCVD on statin therapy (median achieved LDL-C 32 mg/dL vs. 89 mg/dL) followed for a median of 2.2 years. The study database was blindly reviewed to assess characteristics of coronary revascularization procedures. Complex revascularization was the composite of complex PCI (per GLOBAL LEADERS criteria, at least one of: multivessel PCI, 3 or more stents implanted, 3 or more lesions treated, bifurcation PCI with 2 or more stents, or total stent length >60 mm) or CABG. PCI complications included no-reflow, side branch loss, thrombus formation, major dissection, or perforation. The effects of evolocumab on types of revascularization and PCI complications were evaluated using Cox proportional hazards models. Results: 1724 patients underwent revascularization procedures during follow-up. Evolocumab reduced the risk of non-complex PCI by 22% (HR 0.78; 95%CI 0.70-0.88; P<0.001) and the risk of complex revascularization by 29% (HR 0.71; 95%CI 0.61-0.84; P<0.001), including complex PCI by 33% (HR 0.67; 95%CI 0.54-0.84; P<0.001) and CABG by 24% (HR 0.76; 95%CI 0.60-0.96; P=0.019; Figure). The incidence of reported PCI complications tended to be lower with evolocumab (HR 0.74; 95% CI 0.49-1.11). Conclusions: Adding evolocumab to statin therapy reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually. Together with prior coronary imaging findings, these data suggest very aggressive LDL-C lowering to <1 mmol/L has beneficial effects on coronary atherosclerosis burden, anatomical complexity, and the need for intervention.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
考尔菲德发布了新的文献求助20
1秒前
1秒前
赵锦完成签到,获得积分10
1秒前
正好是我应助游哉采纳,获得10
2秒前
学术文献互助应助clamdown采纳,获得100
3秒前
梨糯糯发布了新的文献求助10
4秒前
5秒前
Belinda发布了新的文献求助10
5秒前
缓慢的凝云完成签到,获得积分10
6秒前
传奇3应助Mary采纳,获得10
7秒前
8秒前
黑米粥发布了新的文献求助10
9秒前
doudou完成签到,获得积分10
10秒前
Madeline发布了新的文献求助10
11秒前
11秒前
完美世界应助大胆的以冬采纳,获得10
13秒前
我是老大应助王木木采纳,获得10
13秒前
程瑞哲发布了新的文献求助10
14秒前
欣慰的小懒猪给欣慰的小懒猪的求助进行了留言
14秒前
14秒前
闪闪的YOSH完成签到,获得积分10
15秒前
lina关注了科研通微信公众号
16秒前
呆萌山彤发布了新的文献求助10
19秒前
20秒前
我不是很帅完成签到,获得积分10
20秒前
mingyue完成签到,获得积分10
20秒前
22秒前
24秒前
YifanWang应助皮皮茶哇采纳,获得30
24秒前
无花果应助晴小阳采纳,获得10
25秒前
妮妮完成签到 ,获得积分10
26秒前
54zxy发布了新的文献求助10
28秒前
黑米粥发布了新的文献求助10
28秒前
鲍亚东完成签到 ,获得积分20
29秒前
小伟跑位完成签到,获得积分10
29秒前
鱼贝贝发布了新的文献求助10
29秒前
nnnn完成签到,获得积分10
30秒前
30秒前
时不我待完成签到,获得积分10
31秒前
风华完成签到,获得积分10
32秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Introduction to Helicopter and Tiltrotor Flight Simulation, Second Edition 2500
卤化钙钛矿人工突触的研究 2000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Malcolm Fraser : a biography 700
Signals, Systems, and Signal Processing 610
Materials selection in mechanical design 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6504580
求助须知:如何正确求助?哪些是违规求助? 8298904
关于积分的说明 17714973
捐赠科研通 5604046
什么是DOI,文献DOI怎么找? 2919895
邀请新用户注册赠送积分活动 1897274
关于科研通互助平台的介绍 1759138